News
SKYE
0.8296
+14.76%
0.1067
Weekly Report: what happened at SKYE last week (0406-0410)?
Weekly Report · 1d ago
Skye Bioscience To Highlight Its Approach To Enhancing GLP‑1 Efficacy While Reducing Safety Risks At GLP-1-Based Therapeutics Summit In Boston
Benzinga · 04/07 11:21
Skye Bioscience CEO presents nimacimab-GLP-1 obesity combination strategy at GLP-1 therapeutics summit
Reuters · 04/07 11:04
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Barchart · 04/07 06:00
Skye Bioscience announces annual shareholder meeting via webcast
Reuters · 04/06 20:16
Skye Bioscience corrects option repricing share count to 2,458,158 shares
Reuters · 04/06 20:11
Weekly Report: what happened at SKYE last week (0330-0403)?
Weekly Report · 04/06 09:15
Skye Bioscience names John P. Sharp CFO
Reuters · 04/03 20:47
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Reuters · 04/02 15:48
BUZZ-U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Reuters · 04/02 13:12
BUZZ-Skye Bioscience rises as it begins testing higher doses of obesity drug
Reuters · 04/02 11:45
Skye Bioscience publishes corporate presentation on nimacimab obesity drug, semaglutide combination strategy
Reuters · 04/02 11:19
Skye Bioscience Treats First Patient In Part C Expansion Study Of CBeyond Phase 2a Trial To Characterize Safety And PK At Exposures To Challenge Peripheral Restriction Of Nimacimab Through IV Administration Over 16 Weeks Of Treatment
Benzinga · 04/02 11:12
Skye Bioscience doses first patient in higher-dose nimacimab Phase 2a expansion study
Reuters · 04/02 11:04
SKYE BIOSCIENCE INC - TOPLINE DATA FROM EXPANSION STUDY EXPECTED IN Q4 2026
Reuters · 04/02 11:00
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Barchart · 04/02 06:00
Skye Bioscience investor presentation spotlights nimacimab-semaglutide combo weight-loss data
Reuters · 04/01 18:33
Weekly Report: what happened at SKYE last week (0323-0327)?
Weekly Report · 03/30 09:15
Weekly Report: what happened at SKYE last week (0316-0320)?
Weekly Report · 03/23 09:14
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice
TipRanks · 03/19 22:02
More
Webull provides a variety of real-time SKYE stock news. You can receive the latest news about Skye Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.